Yi Sang
- Cancer Research top 5%
- MicroRNA in disease regulation 10
- Cancer-related molecular mechanisms research 6
- Molecular Biology top 10%
- Epigenetics and DNA Methylation 16
- RNA modifications and cancer 14
- Cancer-related gene regulation 8
- Histone Deacetylase Inhibitors Research 4
- Geriatrics and Gerontology top 10%
-
- interferon and immune responses 3
-
- Cancer Mechanisms and Therapy 3
- Journals
- Scientific Reports (3 papers)Oncotarget (3 papers)Journal of Cellular Physiology (2 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Yi Sang
42 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 84
- Cancer Research 433
- Molecular Biology 885
- Oncology 220
- Geriatrics and Gerontology 30
- Immunology 98
Countries citing papers authored by Yi Sang
This map shows the geographic impact of Yi Sang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Sang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Sang more than expected).
Fields of papers citing papers by Yi Sang
This network shows the impact of papers produced by Yi Sang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Sang. The network helps show where Yi Sang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yi Sang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 4 | |
| 3 | 2022 | 2 | |
| 4 | 2022 | 5 | |
| 5 | 2021 | 12 | |
| 6 | 2021 | 33 | |
| 7 | 2021 | 39 | |
| 8 | 2021 | 2 | |
| 9 | 2020 | 18 | |
| 10 | 2020 | 68 | |
| 11 | THAP7 promotes cell proliferation by regulating the G1/S phase transition via epigenetically silencing p21 in lung adenocarcinoma | 2019 | 1 |
| 12 | 2019 | 5 | |
| 13 | 2016 | 57 | |
| 14 | 2015 | 16 | |
| 15 | 2015 | 2 | |
| 16 | 2013 | 30 | |
| 17 | 2012 | 55 | |
| 18 | 2012 | 5 | |
| 19 | 2011 | 45 | |
| 20 | 2010 | 17 |
About Yi Sang
Yi Sang is a scholar working on Cancer Research, Molecular Biology, Pathology and Forensic Medicine, Oncology and Immunology, having authored 44 papers that have together received 1.1k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (16 papers), RNA modifications and cancer (14 papers), MicroRNA in disease regulation (10 papers), Cancer-related gene regulation (8 papers), Cancer-related molecular mechanisms research (6 papers), Histone Deacetylase Inhibitors Research (4 papers), interferon and immune responses (3 papers) and Cancer Mechanisms and Therapy (3 papers). The work is most often cited by research in Cancer Research (433 citations), Molecular Biology (885 citations), Oncology (220 citations), Geriatrics and Gerontology (30 citations) and Immunology (98 citations). Yi Sang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Tiebang Kang, Chun Cheng, Kaishun Hu, Jianjun Tang, Guofu Huang, Siwei Li, Ruhua Zhang, Yi-Xin Zeng, Lijuan Liu and Yuanzhong Wu. Their work appears in journals such as Scientific Reports, Oncotarget, Journal of Cellular Physiology, The Journal of Pathology and Annals of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.